SCHEMBL20437193

SCHEMBL20437193

Cc1ccc(Cn2ccc3c(Br)ccnc32)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.42
MAPT P10636 1/20 0.42
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
CYP19A1 P11511 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 2/20 0.39
LMNA P02545 2/20 0.39
KCNH2 Q12809 2/20 0.39
SCN5A Q14524 2/20 0.39
SCN9A Q15858 2/20 0.39
FGFR1 P11362 1/20 0.37
FGFR4 P22455 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 1/20 0.37
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
THRB P10828 1/20 0.36
HDAC6 Q9UBN7 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15712169 0.85 NOTUM (0.47) KCNH2SCN5ASCN9AL3MBTL1
SCHEMBL2887633 0.85 SCN9A (0.42) CYP11B1KCNH2SCN5ASCN9AFGFR1
SCHEMBL29663821 0.85 ABL1 (0.48) TP53MAPTCYP11B1CYP11B2LMNA
SCHEMBL660025 0.85 ABL1 (0.48) TP53MAPTCYP11B1CYP11B2LMNA
SCHEMBL16794890 0.81 MEN1 (0.51) TP53MAPTSMN1; SMN2FGFR1FGFR4
SCHEMBL16804211 0.79 MAPK10 (0.46) CYP11B2SMN1; SMN2HTTLMNAFGFR1
SCHEMBL23107520 0.73 NOTUM (0.47) TP53SMN1; SMN2HTTKCNH2SCN5A
SCHEMBL18552967 0.72 MGAM (0.33)
SCHEMBL21821580 0.72 CNR1 (0.42) TP53MEN1POLBKMT2A
SCHEMBL30622723 0.72 CNR1 (0.42) TP53MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180215758-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2018-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180215758-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS ROCK1, ROCK2, CIT TP53 4673/4885MAPT 1740/4885CYP11B1 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.